57179-69-8

Usage

Uses

Used in Pharmaceutical Synthesis:
3,6-DiMethyl-5-nitropyridin-2-ol is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows it to be a versatile building block for the development of new drugs, particularly those targeting specific biological pathways or diseases.
Used in Pesticide Manufacturing:
In the agricultural industry, 3,6-DiMethyl-5-nitropyridin-2-ol is used as a component in the manufacturing of certain pesticides. Its chemical properties contribute to the effectiveness of these products in controlling pests and protecting crops.
Used in Dye Production:
3,6-DiMethyl-5-nitropyridin-2-ol also finds application in the production of dyes, where its chemical structure imparts color and stability to the final product. This makes it valuable in industries such as textiles, where colorfast dyes are essential.
Safety and Environmental Considerations:
Given its potential toxicity and environmental impact, 3,6-DiMethyl-5-nitropyridin-2-ol is classified as a hazardous substance. It should be handled with care, using appropriate safety measures to minimize risks to human health and the environment.

Upstream product

• 1188407-29-5 2-methoxy-3,6-dimethyl-5-nitropyridine 
• 89694-10-0 2-methoxy-3-methyl-5-nitropyridine 
• 1188407-20-6 2-(6-methoxy-5-methyl-3-nitropyridin-2-yl)acetic acid 
• 1188407-19-3 tert-butyl 2-(6-methoxy-5-methyl-3-nitropyridin-2-yl)acetate 

Downstream Products

• 1188407-45-5 (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile 

Relevant academic research and scientific papers

NEW 6-MEMBERED HETEROAROMATIC SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS

The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

Development of an efficient synthesis of two CRF antagonists for the treatment of neurological disorders

BMS-764459 (1) and BMS-763534 (2) are CRF1 antagonists for the treatment of neurological disorders such as depression and anxiety. An efficient synthesis of 1 and 2 is described, which features an efficient palladium-catalyzed cyanation of a 5-chloropyraz

Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity

The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neurological diseases including depression, anxiety related disorders, irritable bowel syndrome, addiction and negative aspects of drug and alcohol withdrawal, and other conditions associated with CRF.

A strategy to minimize reactive metabolite formation: Discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2, 5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist

Detailed metabolic characterization of 8, an earlier lead pyrazinone-based corticotropin-releasing factor-1 (CRF1) receptor antagonist, revealed that this compound formed significant levels of reactive metabolites, as measured by in vivo and in vitro biotransformation studies. This was of particular concern due to the body of evidence suggesting that reactive metabolites may be involved in idiosyncratic drug reactions. Further optimization of the structure-activity relationships and in vivo properties of pyrazinone-based CRF1 receptor antagonists and studies to assess the formation of reactive metabolites led to the discovery of 19e, a high affinity CRF1 receptor antagonist (IC50= 0.86 nM) wherein GSH adducts were estimated to be only 0.1% of the total amount of drug-related material excreted through bile and urine, indicating low levels of reactive metabolite formation in vivo. Anovel 6-(difluoromethoxy)-2,5-dimethylpyridin-3- amine group in 19e contributed to the potency and improved in vivo properties of this compound and related analogues. 19e had excellent pharmacokinetic properties in rats and dogs and showed efficacy in the defensive withdrawal model of anxiety in rats. The lowest efficacious dose was 1.8 mg/kg. The results of a two-week rat safety study with 19e indicated that this compound was well-tolerated.